CLLS News

Cellectis to Report Second Quarter Financial Results on August 6, 2026

Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio

Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026

Celltaxis Names Co-Founder Eileen Heffernan as CEO to Accelerate Growth and Expand Leadership in Lymphatic Disease Therapeutics

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL

Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026

Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress

Cellectis Reports Financial Results for the First Quarter 2026

Cellectis to Report First Quarter Financial Results on May 11, 2026